CureVac(CVAC) - 2021 Q4 - Annual Report

Exhibit 99.1 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update · Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone o Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation o Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vac ...